Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration.
La Rocca C, Carbone F, De Rosa V, Colamatteo A, Galgani M, Perna F, Lanzillo R, Brescia Morra V, Orefice G, Cerillo I, Florio C, Maniscalco GT, Salvetti M, Centonze D, Uccelli A, Longobardi S, Visconti A, Matarese G. La Rocca C, et al. Among authors: florio c. Metabolism. 2017 Dec;77:39-46. doi: 10.1016/j.metabol.2017.08.011. Epub 2017 Sep 8. Metabolism. 2017. PMID: 29132538 Free PMC article.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, Spitaleri DL, Iuliano G, Tedeschi G, Della Corte M, Bonavita S, Matarese G. Carrieri PB, et al. Among authors: florio c. Metabolism. 2015 Sep;64(9):1112-21. doi: 10.1016/j.metabol.2015.05.001. Epub 2015 May 8. Metabolism. 2015. PMID: 25986733
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. Lanzillo R, et al. Among authors: florio c. Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. Mult Scler. 2016. PMID: 26466947 Clinical Trial.
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinvia A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M. Amato MP, et al. Among authors: florio c. Brain. 2020 Oct 1;143(10):3013-3024. doi: 10.1093/brain/awaa251. Brain. 2020. PMID: 32935843
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Portaccio E, et al. JAMA Neurol. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. JAMA Neurol. 2022. PMID: 35877104 Free PMC article. Clinical Trial.
Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
Lanzillo R, Prinster A, Scarano V, Liuzzi R, Coppola G, Florio C, Salvatore E, Schiavone V, Brunetti A, Muto M, Orefice G, Alfano B, Bonavita V, Brescia Morra V. Lanzillo R, et al. Among authors: florio c. J Neurol Sci. 2006 Jun 15;245(1-2):141-5. doi: 10.1016/j.jns.2005.08.023. Epub 2006 Apr 19. J Neurol Sci. 2006. PMID: 16626758 Clinical Trial.
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group. Lugaresi A, et al. Among authors: florio c. BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7. BMC Neurol. 2012. PMID: 22390218 Free PMC article. Clinical Trial.
GABAA receptor autoimmunity after alemtuzumab treatment for multiple sclerosis.
Maniscalco GT, Mariotto S, Höftberger R, Capra R, Servillo G, Manzo V, Napolitano M, Candelaresi P, Gerevini S, Ferrari S, Bozzetti S, Spatola M, Florio C. Maniscalco GT, et al. Among authors: florio c. Neurology. 2020 Sep 1;95(9):399-401. doi: 10.1212/WNL.0000000000010310. Epub 2020 Jul 10. Neurology. 2020. PMID: 32651290 No abstract available.
156 results